Fundraising Fox
Iterion Therapeutics
Founded 2015 · 15 employees on LinkedIn · 3 known investors
Find your way into Iterion Therapeutics
Sign up to see every warm intro you have to Iterion Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Iterion Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Iterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/β-catenin pathway. Its lead candidate is in clinical trials for advanced hepatocellular carcinoma and other Wnt-driven tumors such as colorectal cancer.
Founders & leadership
Investors · 3
Related companies · 2
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Esperion TherapeuticsBiopharma developing HDL-C regulating therapies; listed 2000.
Companies working in the same space as Iterion Therapeutics.
Frequently asked questions
- What does Iterion Therapeutics do?
- Iterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/β-catenin pathway. Its lead candidate is in clinical trials for advanced hepatocellular carcinoma and other Wnt-driven tumors such as colorectal cancer.
- Who are Iterion Therapeutics's investors?
- Iterion Therapeutics's investors include Green Park & Golf Ventures, Lumira Ventures, Portal Innovations.